$SGMO
Sangamo Therapeutics Inc

2017 Q3 Form 10-Q Financial Statement

#000156459017023266 Filed on November 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $11.81M $2.823M
YoY Change 318.42% -67.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.420M $5.020M
YoY Change 27.89% 10.09%
% of Gross Profit
Research & Development $18.43M $17.01M
YoY Change 8.32% 1.92%
% of Gross Profit
Depreciation & Amortization $400.0K $200.0K
YoY Change 100.0% -33.33%
% of Gross Profit
Operating Expenses $24.85M $22.03M
YoY Change 12.79% 3.65%
Operating Profit -$13.04M
YoY Change
Interest Expense $680.0K $240.0K
YoY Change 183.33% 140.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$12.35M -$18.97M
YoY Change -34.89% 50.73%
Income Tax $0.00 -$3.000K
% Of Pretax Income
Net Earnings -$12.35M -$18.97M
YoY Change -34.86% 105.14%
Net Earnings / Revenue -104.59% -671.8%
Basic Earnings Per Share
Diluted Earnings Per Share -$147.5K -$268.6K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $236.7M $155.1M
YoY Change 52.62% -29.29%
Cash & Equivalents $29.89M $27.99M
Short-Term Investments $206.8M $127.1M
Other Short-Term Assets $1.700M $1.500M
YoY Change 13.33% 50.0%
Inventory
Prepaid Expenses
Receivables $3.400M $1.500M
Other Receivables $500.0K $300.0K
Total Short-Term Assets $242.3M $148.8M
YoY Change 62.84% -34.65%
LONG-TERM ASSETS
Property, Plant & Equipment $8.500M $4.900M
YoY Change 73.47% 59.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.30M $9.500M
YoY Change 71.58%
Other Assets $1.000M $200.0K
YoY Change 400.0% 8.11%
Total Long-Term Assets $27.50M $16.20M
YoY Change 69.75% 235.2%
TOTAL ASSETS
Total Short-Term Assets $242.3M $148.8M
Total Long-Term Assets $27.50M $16.20M
Total Assets $269.8M $165.0M
YoY Change 63.52% -29.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.10M $6.300M
YoY Change 60.32% -29.21%
Accrued Expenses $4.500M $2.800M
YoY Change 60.71% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $42.90M $13.90M
YoY Change 208.63% -37.1%
LONG-TERM LIABILITIES
Long-Term Debt $3.900M $2.300M
YoY Change 69.57%
Other Long-Term Liabilities $36.30M $5.000M
YoY Change 626.0% -26.47%
Total Long-Term Liabilities $40.20M $7.300M
YoY Change 450.68% 7.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.90M $13.90M
Total Long-Term Liabilities $40.20M $7.300M
Total Liabilities $83.10M $21.10M
YoY Change 293.84% -27.24%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $186.7M $143.8M
YoY Change
Total Liabilities & Shareholders Equity $269.8M $165.0M
YoY Change 63.51% -29.03%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$12.35M -$18.97M
YoY Change -34.86% 105.14%
Depreciation, Depletion And Amortization $400.0K $200.0K
YoY Change 100.0% -33.33%
Cash From Operating Activities -$15.70M -$17.60M
YoY Change -10.8% 23.94%
INVESTING ACTIVITIES
Capital Expenditures -$700.0K -$100.0K
YoY Change 600.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities -$26.40M $32.20M
YoY Change -181.99% 45.05%
Cash From Investing Activities -$27.10M $32.10M
YoY Change -184.42% 46.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.800M 600.0K
YoY Change 366.67% -96.2%
NET CHANGE
Cash From Operating Activities -15.70M -17.60M
Cash From Investing Activities -27.10M 32.10M
Cash From Financing Activities 2.800M 600.0K
Net Change In Cash -40.00M 15.10M
YoY Change -364.9% -35.74%
FREE CASH FLOW
Cash From Operating Activities -$15.70M -$17.60M
Capital Expenditures -$700.0K -$100.0K
Free Cash Flow -$15.00M -$17.50M
YoY Change -14.29% 25.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-131000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1030000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
71000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
186652000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
269791000
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84104791
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84104791
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18968000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61957000
CY2016Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
238000
us-gaap Interest And Other Income
InterestAndOtherIncome
1118000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
77000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62729000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41477000
us-gaap Interest And Other Income
InterestAndOtherIncome
668000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
310000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62061000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-27000
us-gaap Share Based Compensation
ShareBasedCompensation
6969000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-54000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-27000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
3000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1039000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
725000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1919000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
89000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
56078000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4087000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
28021000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-54115000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-105375000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
11859000
sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
81573000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
760000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
760000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-41496000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27986000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2202000
CY2017Q3 sgmo Build To Suit Lease Costs Capitalized
BuildToSuitLeaseCostsCapitalized
3800000
CY2017Q3 sgmo Assets Amortized Cost
AssetsAmortizedCost
237946000
CY2016Q4 sgmo Assets Amortized Cost
AssetsAmortizedCost
139416000
CY2017Q3 sgmo Assets Accumulated Gross Unrealized Gain Before Tax
AssetsAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2016Q4 sgmo Assets Accumulated Gross Unrealized Gain Before Tax
AssetsAccumulatedGrossUnrealizedGainBeforeTax
76000
CY2017Q3 sgmo Assets Accumulated Gross Unrealized Loss Before Tax
AssetsAccumulatedGrossUnrealizedLossBeforeTax
103000
CY2016Q4 sgmo Assets Accumulated Gross Unrealized Loss Before Tax
AssetsAccumulatedGrossUnrealizedLossBeforeTax
26000
CY2017Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
237845000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
139466000
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2016 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2017Q3 sgmo Cash Equivalents And Available For Sale Securities Mature Within Twenty Four Months
CashEquivalentsAndAvailableForSaleSecuritiesMatureWithinTwentyFourMonths
16300000
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2219000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2735000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6969000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13128000
CY2015Q4 sgmo Build To Suit Lease Property Leased
BuildToSuitLeasePropertyLeased
41400
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-12-31
CY2015Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2015Q4 sgmo Operating Leases Number Of Extension Options
OperatingLeasesNumberOfExtensionOptions
2

Files In Submission

Name View Source Status
0001564590-17-023266-index-headers.html Edgar Link pending
0001564590-17-023266-index.html Edgar Link pending
0001564590-17-023266.txt Edgar Link pending
0001564590-17-023266-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-10q_20170930.htm Edgar Link pending
sgmo-20170930.xml Edgar Link completed
sgmo-20170930.xsd Edgar Link pending
sgmo-20170930_cal.xml Edgar Link unprocessable
sgmo-20170930_def.xml Edgar Link unprocessable
sgmo-20170930_lab.xml Edgar Link unprocessable
sgmo-20170930_pre.xml Edgar Link unprocessable
sgmo-ex311_11.htm Edgar Link pending
sgmo-ex312_7.htm Edgar Link pending
sgmo-ex321_8.htm Edgar Link pending
Show.js Edgar Link pending